NanoViricides, Inc. (NYSE American: NNVC) announced it has received National Ethics Committee approval in the Democratic Republic of the Congo (DRC) for a Phase II clinical trial evaluating its NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company is preparing to submit a Clinical Trial Application to the DRC regulatory agency, ACOREP, and noted that NV-387 drug product is already in the country for an upcoming Phase II Mpox trial, enabling rapid trial initiation if regulatory approval is received.
NanoViricides said NV-387 is the only orally administered Ebola treatment currently under consideration for clinical evaluation, offering potential advantages over infusion-based therapies in resource-limited outbreak settings. The company believes its broad-spectrum antiviral platform, designed to target host-cell features used by viruses, could provide a treatment option for Bundibugyo and other ebolaviruses that currently have no approved therapies or vaccines.
The approval marks a significant step for NanoViricides, which is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company's advanced drug candidate for Shingles, NV-HHV-1, is also in development.
The company's technology is based on intellectual property, technology, and proprietary know-how of TheraCour Pharma, Inc., and NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for treating various human viral diseases, including Ebola/Marburg viruses. The company's business model relies on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses.
NanoViricides is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. For more information, visit the company's newsroom at https://ibn.fm/NNVC.
To view the full press release, visit https://ibn.fm/MuxOe.
